Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay
Movement Disorders · 2026-05 · 41 (5) · 1114-1127
DOI: 10.1002/mds.70197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 28.01.2026. Verfasst von Sarah M Brooker und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Parkinson Disease, alpha-Synuclein. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research, NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Background
The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Objectives
Describe clinical and neuroimaging characteristics of CSFasynSAA‐negative sPD individuals in the Parkinson's Progression Markers Initiative (PPMI).
Methods
We identified sPD PPMI participants with a negative CSFasynSAA (SAA−, n = 80) or positive CSFasynSAA (SAA+, n = 856) result at baseline. For comparative analysis between groups, we used a reduced dataset (n = 79 SAA− and n = 237 SAA+) propensity‐score matched on age, sex, and time since clinical diagnosis. Clinical parameters, dopamine transporter‐single photon emission computed tomography (DAT‐SPECT), and magnetic resonance imaging (MRI) brain volumetrics were analyzed.
Results
The SAA− and matched SAA+ groups had similar motor performance on the Movement Disorder Society Unified Parkinson's Disease Rating Scale‐Part III (MDS‐UPDRS‐III) and similar cognitive performance on the Montreal Cognitive Assessment (MoCA) at baseline. The proportion with severe hyposmia was 12% for SAA− versus 73% for SAA+ ( P < 0.001). Per PPMI enrollment criteria all participants were classified as having an abnormal DAT‐SPECT. There were no significant differences in median quantitative DAT‐SPECT measures between groups. The SAA− group showed a higher degree of atrophy in subcortical brain regions including substantia nigra. Longitudinally, 14.3% of SAA− participants had a change in diagnosis versus 0.9% of SAA+ participants.
Conclusions
At baseline, SAA− sPD PPMI participants have a substantially lower rate of hyposmia, but otherwise cannot be readily distinguished from SAA+ participants based on clinical characteristics. However, SAA− participants have a greater degree of subcortical brain atrophy, and approximately one out of seven SAA− participants received a change in diagnosis. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
- Division of Neurology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.
- Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada.
ORCID-Profile: Sarah M Brooker, Seung Ho Choi, Seyed-Mohammad Fereshtehnejad, Un Jung Kang, Ethan G Brown, Daniel Weintraub
Förderung
- Michael J. Fox Foundation for Parkinson's Research
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Brooker, S. M., Pasquini, J., Choi, S. H., Lafontant, D. E., Fereshtehnejad, S. M., Zeighami, Y., Grillo, P., Riboldi, G. M., Azizi, H., Moqadam, R., Kang, U. J., Nudelman, K. N. H., Siderowf, A., Tanner, C. M., Tropea, T. F., Foroud, T., Chahine, L. M., Mollenhauer, B., Merchant, K. M., …, & Parkinson's Progression Markers Initiative (2026). Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay. Movement Disorders, 41(5), 1114-1127. https://doi.org/10.1002/mds.70197
Vancouver
Brooker SM, Pasquini J, Choi SH, Lafontant DE, Fereshtehnejad SM, Zeighami Y, et al. Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay. Movement Disorders. 2026;41(5):1114-1127. doi:10.1002/mds.70197
BibTeX
@article{Brooker2026,
author = {Brooker, Sarah M and Pasquini, Jacopo and Choi, Seung Ho and Lafontant, David-Erick and Fereshtehnejad, Seyed-Mohammad and Zeighami, Yashar and Grillo, Piergiorgio and Riboldi, Giulietta M and Azizi, Houman and Moqadam, Roqaie and Kang, Un Jung and Nudelman, Kelly N H and Siderowf, Andrew and Tanner, Caroline M and Tropea, Thomas F and Foroud, Tatiana and Chahine, Lana M and Mollenhauer, Brit and Merchant, Kalpana M and Galasko, Douglas and Coffey, Christopher S and Dobkin, Roseanne D and Brown, Ethan G and Alcalay, Roy N and Weintraub, Daniel and Marek, Kenneth and Simuni, Tanya and Gonzalez-Latapi, Paulina and Pavese, Nicola and Poston, Kathleen L and Parkinson's Progression Markers Initiative, Parkinson's Progression Markers Initiative},
title = {Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay},
journal = {Movement Disorders},
year = {2026},
volume = {41},
number = {5},
pages = {1114--1127},
doi = {10.1002/mds.70197}
}
EUVIMED